# OnCo record trastuzumab-deruxtecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trastuzumab-deruxtecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trastuzumab-deruxtecan" ;
  schema:name "Trastuzumab deruxtecan"@en ;
  schema:description "Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer."@en ;
  schema:url <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q80109553> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20deruxtecan>, <https://www.nice.org.uk/guidance/ta992>, <https://doi.org/10.1038/s41591-025-03981-4>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ENHERTU%22>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Enhertu" ;
  onco:approval "US 2019: HER2+ metastatic breast cancer, ≥2 prior anti-HER2 regimens", "US 2022: HER2-low metastatic breast cancer; HER2-mutant NSCLC", "US 2024: HER2 IHC3+ solid tumours (tumour-agnostic)", "US 2025: HER2-low/ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)", "US 2026: Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)", "EU 2023: Unresectable or metastatic HER2-low breast cancer after chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy (DESTINY-Breast04), hormone-receptor-negative disease included", "UK 2024: HER2-low metastatic or unresectable breast cancer after chemotherapy: NICE TA992 (29 July 2024) does not recommend trastuzumab deruxtecan, the cost per quality-adjusted life year being above the range NICE accepts; a rapid review (GID-TA12551) is in development", "US 2024: Unresectable or metastatic HER2-positive (IHC 3+) solid tumours after previous systemic treatment, including colorectal cancer" ;
  onco:acceleratedApproval "US 2019-12-20: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting", "US 2022-08-11: Adult patients with unresectable or metastatic NSCLC whose tumors have an activating HER2 (ERBB2) mutation, as detected by an FDA-approved test, and who have received a prior systemic therapy", "US 2024-04-05: Adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options." ;
  onco:acceleratedApprovalConfirmed "US 2022-05-04: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting" ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-ihc-2-plus/>, <https://onco.cc/biomarkers/her2-ihc-1-plus/>, <https://onco.cc/biomarkers/her2-ihc-0/>, <https://onco.cc/biomarkers/her2-low-ihc/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/salivary-duct-carcinoma/>, <https://onco.cc/cancers/her2-amplified-colorectal/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/>, <https://onco.cc/cancers/her2-mutant-nsclc/>, <https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/bystander-effect/>, <https://onco.cc/terms/ggfg/>, <https://onco.cc/terms/her2-testing-in-biliary-cancer/> ;
  onco:trials <https://onco.cc/trials/destiny-breast03/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/trials/destiny-breast09/>, <https://onco.cc/trials/destiny-breast11/>, <https://onco.cc/trials/nct06899126/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct06819007/>, <https://onco.cc/trials/nct06174987/>, <https://onco.cc/trials/nct05048797/>, <https://onco.cc/trials/nct07022483/>, <https://onco.cc/trials/nct04639219/>, <https://onco.cc/trials/nct04644068/>, <https://onco.cc/trials/nct06324357/>, <https://onco.cc/trials/nct05246514/>, <https://onco.cc/trials/nct05824975/>, <https://onco.cc/trials/nct06525298/>, <https://onco.cc/trials/nct06731478/>, <https://onco.cc/trials/nct07497386/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct07060807/>, <https://onco.cc/trials/nct04538742/>, <https://onco.cc/trials/nct06467357/>, <https://onco.cc/trials/nct05417594/>, <https://onco.cc/trials/nct04379596/>, <https://onco.cc/trials/nct07069712/>, <https://onco.cc/trials/nct05950945/>, <https://onco.cc/trials/nct06271837/>, <https://onco.cc/trials/nct03742102/>, <https://onco.cc/trials/nct06832202/>, <https://onco.cc/trials/destiny-crc01/>, <https://onco.cc/trials/destiny-pantumor02/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/>, <https://onco.cc/key-papers/paper-destiny-gastric01-nejm-2020/>, <https://onco.cc/key-papers/paper-destiny-lung01-nejm-2022/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/>, <https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/>, <https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/>, <https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/> .